



## Nicox convenes General Meeting to vote on Acix acquisition on October 22, 2014

.....  
September 10, 2014.

Sophia Antipolis, France.

**Nicox S.A.** (NYSE Euronext Paris: COX) has published a notice to convene an Ordinary and Extraordinary General Meeting (EGM) on Wednesday, October 22, 2014, at 2:00 pm CET at the Hotel Mercure, rue Albert Caquot, 06560 Sophia Antipolis, France, to approve resolutions including the proposed acquisition of Acix Therapeutics, Inc.

On July 2, 2014, Nicox announced the signature of an agreement to acquire Acix Therapeutics, a private, US-based, ophthalmic pharmaceutical development company with a strong near-term pipeline of therapeutics addressing major segments of the ophthalmic market, including allergy and inflammation. The proposed acquisition represents a significant step forward in Nicox's strategy of creating an international ophthalmic company built around therapeutics and diagnostics. For more information, please refer to the [Nicox press release dated July 2, 2014](#), as well as the [conference call presentation](#) and [audio recording](#), available on Nicox's website [www.nicox.com](http://www.nicox.com).

The draft resolutions also include the proposed appointment to Nicox's Board of Directors of Les Kaplan, Executive Chairman of Acix, subject to the prior approval of the acquisition of Acix, as well as several financial authorizations that will give Nicox the flexibility to take advantage of opportunities which may help the Company to implement its growth strategy. The appointments to the Board of Dr. Adrienne Graves, former CEO of Santen Inc., and Luzi von Bidder, former Chairman of Acino Holding AG, who were co-opted in August 2014, will also be submitted to Nicox's shareholders for approval.

To participate in the EGM, shareholders can either request an admission card to attend the meeting in person or send a signed proxy or voting form to Nicox<sup>1</sup> or to Société Générale<sup>2</sup>. Shareholders who hold their share 'in bearer form' (*au porteur*) must also provide a share certificate from the financial intermediary holding their shares. In addition, an e-voting platform will be implemented as of September 29, 2014 to allow shareholders to vote via Internet. Full information on voting can be found on the "How to Vote" button on Nicox's website and under [Investor Information / Shareholder Meetings](#). The documents referred to in articles L.225-115, R. 225-81 and R. 225-83 of the French Code de Commerce, including the proxy voting

form, will be sent to shareholders upon written request in accordance with the legal timing requirements. These documents will also be made available to shareholders at the headquarters and on the website of the Company ([www.nicox.com](http://www.nicox.com)) at the latest on October 1<sup>st</sup>, 2014.

In the event that the required 25% quorum is not reached on the first call, Nicox will convene a shareholder meeting on a second call on Wednesday, November 5, 2014 at 2:00 pm CET at the Hotel Mercure, rue Albert Caquot, 06560 Sophia Antipolis, France.

.....

#### Notes

1. Nicox S.A., Drakkar D, 2405 route des Dolines, CS 10313 Sophia Antipolis, 06560 Valbonne, France.
  2. Société Générale Securities Services, Service Assemblées Générales, CS 30812, 44308 Nantes Cedex 03, France.
- .....



#### **About Nicox**

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is latanoprostene bunod, a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit [www.nicox.com](http://www.nicox.com).

.....

**This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.**

**Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2013 » filed with the French Autorité des Marchés Financiers (AMF) on April 2, 2014 and available on Nicox's website ([www.nicox.com](http://www.nicox.com)) and on the AMF's website ([www.amf-france.org](http://www.amf-france.org)).**



**Contacts**

**Nicox**                      **Gavin Spencer** | Executive Vice President Corporate Development  
+33 (0)4 97 24 53 00 | [communications@nicox.com](mailto:communications@nicox.com)

**Media Relations**

**United States**            **Justin W. Jackson** | Burns McClellan, Inc.  
+1 212 213 0006 | [jjackson@burnsmc.com](mailto:jjackson@burnsmc.com)

**United Kingdom**        **Jonathan Birt**  
+44 7860 361 746 | [jonathan.birt@ymail.com](mailto:jonathan.birt@ymail.com)

**France**                      **Caroline Courme** | Communication Manager  
+33 (0)4 97 24 53 43 | [courme@nicox.com](mailto:courme@nicox.com)